Aspire Pharma Strengthens European Footprint with Caragen Acquisition
Thursday, February 12, 2026
Aspire Pharma Limited, one of the UK’s fastest-growing specialty generics pharmaceutical businesses, has acquired Caragen, a Dublin based pharmaceutical organisation with a strong presence in hospital immunology therapies.
Caragen brings extensive commercial expertise in hospital-based medicines and medical devices alongside being a well-established distribution network serving the pharmaceutical, medical device and healthcare sectors throughout Ireland.
Under the acquisition, Aspire will acquire the Irish distribution rights to 100+ product lines covering a number of therapeutic areas including immunology, oncology, infectious diseases, and medical devices.
Richard Condon, Aspire Pharma Chief Executive, said: “This acquisition strengthens Aspire’s existing portfolio, broadens our reach into new therapeutic areas and significantly enhances our capabilities in Ireland.
“It represents another key milestone in our growth journey and marks the beginning of a new phase of strategic international expansion, as we steadily build our European footprint. By advancing our commercial and technical capabilities in Ireland, we are proud to accelerate our ability to serve patients and deliver meaningful value to healthcare systems across Europe and beyond.”
From a commercial operations standpoint, Caragen will continue to operate as an independent brand in Ireland. The company’s senior management team and dedicated professionals will also remain in place, ensuring a smooth integration and effective knowledge transfer into the broader Aspire Pharma ecosystem.
Andrew O’Connell, Managing Director of Caragen, said: “After building Caragen into a trusted partner for hospital-based therapies across Ireland, we are proud to be joining Aspire Pharma, which shares our commitment to quality, innovation and delivering the highest levels of patient care. We look forward to expanding and accelerating new product launches in current and new channels in Ireland”
Ends
About Aspire Pharma
Aspire was established with a simple mission: To make a difference to the lives of patients through the development and supply of innovative products and medicines throughout the world. Aspire is present in the specialty, niche generics, branded generics, and medical Aspire was established with a simple mission: To make a difference to the lives of patients through the development and supply of innovative products and medicines throughout the world. Aspire is present in the specialty, niche generics, branded generics, and medical device sectors. Aspire was majority acquired by an affiliate of H.I.G. Capital (“H.I.G.”) in 2021. For more information, go to: www.aspirepharma.com.
About H.I.G. Capital
H.I.G. Capital is a leading global alternative investment firm with $74 billion of capital under management.* Based in Miami, and with offices in Atlanta, Boston, Chicago, Dallas, Los Angeles, New York, and San Francisco in the United States, as well as international affiliate offices in Hamburg, London, Luxembourg, Madrid, Milan, Paris, Bogotá, Rio de Janeiro, São Paulo, and Dubai, H.I.G. specializes in providing both debt and equity capital to middle market companies, utilizing a flexible and operationally focused/value-added approach. For more information, please refer to the H.I.G. website at hig.com.
*Based on total capital raised by H.I.G. Capital and affiliates.
Disclosure Notice
The information contained in this release is correct as of 11th February 2026. Aspire assumes no obligation to update forward‐looking statements contained in this release as the result of new information or future events or developments.
This release contains forward-looking information about Aspire’s acquisition that involve substantial risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. Risks and uncertainties include, among other things, risks related to the ability to realise the anticipated benefits of the acquisition, including the possibility that the expected benefits from the acquisition will not be realised; the uncertainties inherent in research and development, including the ability to meet anticipated clinical endpoints, commencement and/or completion dates for clinical trials, regulatory submission dates, regulatory approval dates and/or launch dates, as well as the possibility of unfavourable new clinical data and further analyses of existing clinical data; risks associated with interim data; the risk that clinical trial data are subject to differing interpretations and assessments by regulatory authorities; whether regulatory authorities will be satisfied with the design of and results from the clinical studies; whether and when license applications may be filed in any jurisdictions; whether and when any such applications may be approved by regulatory authorities, which will depend on myriad factors, including making a determination as to whether the product's benefits outweigh its known risks and determination of the product's efficacy and, if approved, the product(s) will be commercially successful.
Media Contact
Email: pressoffice@aspirepharma.com.
Tel: +44 1730 231148
